DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study -

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Epilepsy

Intervention: Lamotrigine tablets 25/100 mg (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline


The purpose of this study is to examine whether the VPA (Valproate) dose can be reduced by additional administration of LTG (Lamotrigine) in Japanese pre-menopausal female epilepsy patients aged 15 years or older, whose seizures are well controlled by VPA monotherapy.

Clinical Details

Official title: Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study -

Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Percentage of subjects and percent reduction of the VPA dose

Secondary outcome:

Number of seizure day(s)

Change in QOLIE-31-P or QOLIE-AD-48

Percentage of subjects completing or discontinuing the study

Change in body weight

To investigate concentration of LTG

Type, severity, and incidence of adverse events

Detailed description: RATIONALE In several studies that investigated the effects of in utero exposure to AEDs (antiepileptic drugs) on fetal malformations and intellectual development in children after birth, it has been reported that VPA causes neonatal malformations and decreases intelligence of children in a dose dependent manner, whereas such a risk is low in LTG (Hernandez-Díaz et al., 2012; Meador et al., 2013). It has also been reported that LTG as adjunctive therapy with VPA is effective in inhibiting seizures in patients with poorly controlled seizures, and adverse events under VPA monotherapy can be relieved by subsequently reducing VPA dose after LTG is combined (Sale et al., 2005; Jozwiak et al., 2000; Morris et al, 2004; Buchanan, 1996). Thus, by considering the benefits of replacing VPA by LTG in childbearing women, we will examine whether VPA dose can be reduced by introducing LTG in Japanese female epilepsy patients under VPA monotherapy (aged ≥ 15 years, pre-menopausal). STUDY DESIGN Single arm, multicenter, and open-label study TIME FRAME

- Screening(Retrospective review of medical records for 12 weeks)

- LTG escalation phase (8-18 weeks)

- VPA reduction phase (3-16 weeks)

- LTG & VPA maintenance phase (12 weeks)

- Follow up (1-4 weeks) PRIMARY OBJECTIVE To examine whether the VPA dose can be reduced

by additional administration of LTG (up to 200 mg/d if there are no safety concerns) in Japanese pre-menopausal female epilepsy patients aged 15 years or older, whose seizures are well controlled by VPA monotherapy (fixed maintenance dose of 400-1200 mg/d). SECONDARY OBJECTIVES

- To investigate the steady state concentration of LTG immediately before VPA dose

reduction, at the time of VPA dose reduction, and during the LTG&VPA maintenance phase.

- To investigate the safety and tolerability associated with additional administration of

LTG followed by dose reduction of VPA.


Minimum age: 15 Years. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria: 1. (Target disease) Epilepsy patients having the following seizure types as classified by the International Classification of Epileptic Seizures

- Partial seizures (with or without secondary generalization)

- Tonic-clonic seizures with or without myoclonus but without other generalized

seizure type(s) 2. Subjects having a confident diagnosis of epilepsy that is uncomplicated by pseudoseizures such as psychogenic nonepileptic seizures 3. Subjects whose seizures have been controlled for 12 weeks prior to start of the investigational product with a stable maintenance dose of VPA monotherapy (400-1200 mg/d) 4. (Age and gender) Japanese pre-menopausal women who are at least 15 years old at the time of consent, not lactating, and can agree to use any of the following types of contraception in a reliable fashion: 1. Complete abstinence during the study as well as for a period after the study to account for elimination of the investigational product (a minimum of 2 weeks) 2. Consistent and correct use of any of the following contraceptive methods

- Surgical sterilization of male partner (i. e., male partner is the sole sexual

partner for the female subject and is sterilized prior to the subject's entry into the study)

- Intrauterine device with a failure rate of less than 1% per year

- Double barrier method (e. g., spermicide plus a condom or a diaphragm) Note:

Women who have had a hysterectomy or tubal ligation are considered to be of non-childbearing potential. Since a pharmacokinetic interaction has been observed between LTG and estrogen-based oral contraceptives, the use of hormonal therapy such as for contraception or hormone replacement therapy is not allowed. 5. Outpatients 6. Subjects who can keep a seizure diary 7. Subjects who can understand and sign the informed consent. If the subject is under 20 years old at the time of consent, both the subject and subject's legally acceptable representative have to sign the consent to participate in the study. 8. QTc <480 msec for subjects with bundle branch block or QTc <450 msec for other subjects, in which QTc is measured by either single or triplicate-averaged ECG 9. Subjects who can comply with dosing of the investigational and standard products and all study procedures Exclusion Criteria: 1. Subjects with a history of hypersensitivity to LTG 2. Subjects with a history of rash associated with other AED treatments. 3. Subjects who have received another AED besides VPA during the 12 weeks prior to start of the investigational product 4. Subjects with status epilepticus during the 6 months prior to start of the investigational product 5. Subjects with a history of substance (including alcohol and drug) dependence or substance abuse as defined by the DSM-IV-TR within 12 months or 1 month, respectively, prior to start of the investigational product 6. Subjects with a severe acute or chronic illness likely to impair drug absorption, distribution, metabolism, or excretion; or subjects with any unstable physical symptom likely to require hospitalization during the study 7. Subjects with a severe psychiatric disorder that affects the procedures of the study or drug assessment 8. Subjects with an acute or progressive neurological disorder or an organic disease 9. Subjects with any clinically significant cardiac, renal, or hepatic medical condition. Any patient with these conditions will be excluded from the study even if these conditions are being controlled with a chronic therapy. 10. Subjects with an unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), cirrhosis, or known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) Note: Chronic stable hepatitis B and C are acceptable if the subjects otherwise meet the inclusion criteria. However, the subjects with chronic stable hepatitis B will be excluded if significant immunosuppressive agents are being administered due to a risk of hepatitis B reactivation. 11. Subjects who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study 12. Subjects who are suspected to have an urea cycle disorder as below:

- Subjects with a history of encephalopathy or coma of unknown cause

- Subjects with a family history of infant death of unknown cause or urea cycle

disorder 13. Subjects taking inducers of LTG glucuronidation (i. e., rifampicinor lopinavir/ritonavir), atazanavir/ritonavir, risperidone, or oral contraceptives or hormone drugs containing estrogen 14. Subjects taking carbapenem antibiotic (i. e., panipenem/betamipron, meropenem hydrate, imipenem hydrate/cilastatin sodium, biapenem, doripenem hydrate, or tebipenem pivoxil) 15. Subjects who have participated in other clinical studies within 3 months prior to start of the investigational product 16. Subjects who have had active suicidal plans/intent or suicidal thoughts in the past 3 months prior to start of the investigational product; or subjects who have history of suicide attempts in the last 1 year prior to start of the investigational product or of multiple suicide attempts in their lifetime 17. Subjects whom the investigator or subinvestigator considers ineligible for the study

Locations and Contacts

GSK Investigational Site, Hyogo 664-8540, Japan

GSK Investigational Site, Kagoshima 892-0844, Japan

GSK Investigational Site, Kyoto 606-8507, Japan

GSK Investigational Site, Osaka 560-8565, Japan

GSK Investigational Site, Saitama 351-8551, Japan

GSK Investigational Site, Shizuoka 430-8558, Japan

GSK Investigational Site, Tokyo 185-0012, Japan

Additional Information

Starting date: April 2014
Last updated: July 2, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017